Team:UCL/Background

From 2013.igem.org

(Difference between revisions)
Line 49: Line 49:
<p class="minor_title">Alzheimer's Disease</p>
<p class="minor_title">Alzheimer's Disease</p>
-
<p class="abstract_text">
+
<p class="abstract_text" style="color:#404040;">
-
Our project this year blends the fields of synthetic biology and neuroscience. We aim to demonstrate that genetic engineering techniques can be applied to the brain, creating synthetic biological systems capable of rectifying abnormalities in the brain on a cellular and macromolecular level.  </p>
+
Our project this year blends the fields of synthetic biology and neuroscience. We aim to demonstrate that genetic engineering techniques can be applied to the brain, creating synthetic biological systems capable of rectifying abnormalities in the brain on a cellular and macromolecular level.  <br></p>
-
<p class="abstract_text">
+
<p class="abstract_text" style="color:#404040;">
Such novel application of synthetic biology could offer new ways to treat brain diseases, such as our target, Alzheimer’s disease, for which most modern pharmaceutical treatment is purely symptomatic. </p>
Such novel application of synthetic biology could offer new ways to treat brain diseases, such as our target, Alzheimer’s disease, for which most modern pharmaceutical treatment is purely symptomatic. </p>
</div>
</div>

Revision as of 17:40, 13 August 2013

BACKGROUND INFO

Alzheimer's Disease

Our project this year blends the fields of synthetic biology and neuroscience. We aim to demonstrate that genetic engineering techniques can be applied to the brain, creating synthetic biological systems capable of rectifying abnormalities in the brain on a cellular and macromolecular level.

Such novel application of synthetic biology could offer new ways to treat brain diseases, such as our target, Alzheimer’s disease, for which most modern pharmaceutical treatment is purely symptomatic.